Introduction {#sec1}
============

Age-related diseases have become a new health care challenge to face in Western countries due to the progressive aging of the population. With the increasing life expectancy, it is estimated that most of the babies born after the year 2000 will live up to their 100th birthday ([@ref10]). Although the efforts to improve the outcome of circulatory diseases have led to a decrease in the mortality associated to them ([@ref49]), these are still the leading cause of death worldwide, and their prevalence is greater in the elderly ([@ref35]; [@ref84]; [@ref20]). Therefore, aging is the principal risk factor for cardiovascular diseases (CVDs), and it is a burden for healing after myocardial infarction ([@ref91]; [@ref58]), which will have a great impact in health care costs ([@ref24]).

Transcriptomic data revealed that the expected scenario of gene expression was wrong. Protein-coding genes account for \<3% of the transcriptome ([@ref59]). The rest are noncoding RNAs (ncRNAs), divided in two classes according to their length, small (including miRNAs, tRNAs, and small nucleolar RNAs) and long ncRNAs (lncRNAs; [@ref77]; [@ref79]). According to the last version of the GENCODE project, the human genome contains 19940 protein-coding genes, 16066 lncRNA genes, and 7577 short ncRNA genes, of which 1881 are miRNAs ([@ref18]). LncRNAs are defined as transcripts longer than 200 nt without coding potential ([@ref52]). They are transcribed by RNA polymerase II in relatively low levels and present little sequence conservation between species ([@ref80]), which complicates their detection and characterization. There are several classifications for lncRNAs depending on genomic localization and orientation (intergenic, intronic, enhancer-associated, sense, antisense, and bidirectional), their subcellular localization (nuclear or cytosolic), and their mechanism of action.

The molecular mechanisms by which lncRNAs exhibit their effects are very diverse and include epigenetic regulation, (post)transcriptional gene regulation, and compartmentalization ([@ref48]). Most of these functions are carried out by binding of the lncRNA to RNA-binding proteins, such as transcription factors, chromatin modifiers, and scaffolding proteins. LncRNAs can also control the localization, interaction, and availability of effectors in a specific site to elicit a specific activity ([@ref50]; [@ref32]; [@ref79]; [@ref72]; [@ref100]). In the past decade, increasing evidence points to a major role of lncRNAs in development and disease, including aging and CVD ([@ref6]; [@ref17]; [@ref33]; [@ref26]). Therefore, lncRNAs are arising as a new frontier for interventional therapy in cardiovascular aging. In this review, we will summarize the recent discoveries of the roles of lncRNAs during aging in the heart.

Aging and senescence in the myocardium {#sec2}
======================================

Aging, at a cellular level, is defined by a well-described series of molecular hallmarks ([@ref46]; [@ref65]). One of them is cellular senescence, a process by which the chromosomal telomeres shorten with each cell division. While this is a physiological consequence of aging, in certain situations, the eroded chromosomal endings tend to fuse, leading to chromosome instability, DNA damage, and eventually apoptosis ([@ref8]). Telomere attrition has been identified as a risk factor for several CVDs, such as myocardial infarction ([@ref5]; [@ref2]), atrial fibrillation ([@ref75]), and cardiomyopathy ([@ref41]; [@ref70]; [@ref73]). Also, an increase in mitochondrial production of reactive oxygen species during senescence further contributes to genomic instability ([@ref34]). Moreover, lifestyle choices contribute to the acquisition of epigenetic marks in the genome that can alter the pattern of gene expression ([@ref35]; [@ref51]), and aging can promote aberrant chromatin modifications ([@ref46]), influencing the development of CVDs ([@ref21]).

These molecular cues of aging have a direct impact on the functionality of cells and tissues in the cardiovascular system. In summary, they promote functional changes that overlap and accumulate, such as vascular stiffness, endothelial dysfunction, altered signaling pathway activation, electrophysiological changes, and reduced proliferation ([@ref65]). At a myocardial level, the interrelation of these aging-related phenotypes will lead to the development of cardiac diseases as cardiac hypertrophy (CH), heart failure (HF) with preserved ejection fraction (HFpEF), acute myocardial infarction (AMI), and arrhythmia (AF). All of these have been found to be caused, influenced, or ameliorated by the action of lncRNAs.

Aging-mediated CH and HF {#sec3}
------------------------

During vascular aging, the increased stiffness of the aorta and endothelial dysfunction lead to stenosis and hypertension, provoking an increase in cardiac mass to cope with a greater demand for pumping. The result of this process is known as CH, and when it is sustained in time, remains irreversible and causes HF ([@ref19]; [@ref25]; [@ref81]).

HF can be classified in two types depending on the preservation of the ejection function. Therefore, we can distinguish between HF with reduced ejection function (HFrEF) or HFpEF. Typically, HFpEF is most prevalent in the elderly and its onset diagnosis is increasing as a consequence of increased aging of the population ([@ref64]). HFpEF is caused by a loss of the myocardium elasticity, which reduces the capability of a correct filling, and results in impaired relaxation and diastolic dysfunction ([@ref69]).

Myocardial infarction is highly prevalent in the elderly {#sec4}
--------------------------------------------------------

The progressive decline in vascular function together with the prolonged lifetime exposure to risk factors in the elderly creates an environment for the development for atherosclerosis, coronary heart disease, and eventually AMI ([@ref92]; [@ref39]; [@ref36]; [@ref58]). AMI is caused by the interruption of blood supply to a part of the heart, therefore causing hypoxia or ischemia of the cardiac muscle. Afterwards, the heart experiences a remodeling phase that often leads to HFrEF ([@ref16]). The survival rates after AMI are also lower with advancing age ([@ref15]).

Arrhythmia, cause and consequence of HF in the elderly {#sec5}
------------------------------------------------------

During aging, cardiomyocytes develop dysfunctional calcium handling that affects their electrophysiological properties, increasing the incidence of AF and arrhythmias in the aged population ([@ref7]; [@ref14]). In aged patients, the increase in left atrial size is another risk factor for AF ([@ref40]).

AF and HF predispose to each other. On one side, AF abruptly changes heart rate ([@ref71]), obligating the heart to increase the force of contraction and therefore promoting CH. On the other side, several aging-prevalent cardiac diseases can lead to ventricular arrhythmia by creating an arrhythmogenic environment and generating fibrotic tissue that interrupts the conduction of the electrical impulse ([@ref16]). The comorbidity of AF and HFpEF in elderly patients results in poor clinical outcomes ([@ref43]).

Mechanism of action of lncRNAs in cardiac diseases {#sec6}
==================================================

The mechanisms by which lncRNAs exert their function are variable and still subject of discussion. In some cases, the same lncRNA has been suggested to act in different diseases or cell types with a specific mechanism for each one. In general, most lncRNAs function by binding to ribonucleoproteins (RNPs) and modulating their functions, but there has been an increase in the identification of lncRNAs that bind to miRNAs to inhibit their interference on the expression of a third target, creating a lncRNA--miRNA--target axis. Also, some lncRNAs bind to DNA targets and attract chromatin modifier proteins, creating RNA--DNA--protein complexes to form nuclear domains ([@ref67]).

We can divide lncRNAs regarding their mechanism of action in five groups, although these mechanisms may overlap and they are not exclusive ([@ref89]; [@ref12]; [Figure 1](#f1){ref-type="fig"}): (i) Signal: the expression of a lncRNA is regulated in response to a stimulus, at a certain developmental time or in a specific cell type, which helps integrating the response to that cellular context to generate quick regulatory changes. Signal lncRNAs usually perform their function toward targets through one of the mechanisms listed below.(ii) Decoy: the lncRNA binds to an RNA-binding protein or an RNA molecule (transcription factors or other regulatory effectors) and inhibits its biological function by sequestering it. LncRNAs acting as miRNA sponges would be included in this group, and, in this case, the suggested term is competitive endogenous RNAs.(iii) Guide: the lncRNA binds to a transcription factor or chromatin modifier and conducts it to the target promoter to alter the expression of a certain gene. This mechanism can occur in cis (on neighboring genes) or in trans (on distant genes).(iv) Scaffold: the lncRNA binds through distinct domains to several RNA-binding proteins, bringing them together so they can interact in macromolecular complexes (RNPs).(v) Enhancer: the lncRNA interacts with both the promoter and enhancer regions of a gene and creates a chromosomal looping to bring them in proximity and stimulates gene expression.

![Classification of lncRNAs according to their molecular mechanism of action.](mjz046f1){#f1}

In the following sections, we will discuss the currently known lncRNAs that are involved in aging-mediated cardiac diseases attending to this mechanistic classification ([Figure 2](#f2){ref-type="fig"}). As exception, we will omit signal lncRNAs. During the onset of a cardiac disease, the expression of a certain lncRNA is sooner or later a consequence of the disease-triggering stimulus; therefore, all of the lncRNAs reviewed here are part of this category as well as they exert their function by one of the other four.

![Prevalent CVDs in the aging heart and lncRNAs associated to them.](mjz046f2){#f2}

Decoy lncRNAs {#sec7}
-------------

In 2014, [@ref23] showed that an antisense transcript to *Myh7*, termed myosin heavy-chain-associated RNA transcripts (*Mhrt*), was downregulated in pressure overloaded hearts and prevents the progression of cardiomyopathy. *Mhrt* originates antisense to the intergenic region between *Myh6* and *Myh7* and was found to mediate the expression switch from *Myh6* to the embryonic *Myh7*, a hallmark of CH ([@ref54]), by binding to *Brg1* in a *cis*-regulated, chromatin modifying feedback circuit ([@ref22]). Also in CH, cardiac-hypertrophy-associated epigenetic regulator (*Chaer*) was described to be downregulated in pressure-overload HF. *Chaer* binds to PRC2 components SUZ12 and EZH2 to interfere with the trimethylation of H3K27, a known suppressive chromatin mark, in their target genes. Thereby, *Chaer* prevents the epigenetic repression of CH-related genes, promoting the development of the disease ([@ref90]).

During an AMI, hypoxia induces the activation of p53 in cardiomyocytes that upregulates maternally expressed gene 3 (*Meg3*) expression ([@ref93]). *MEG3* has been described to act as a scaffold for the PRC2 complex, bringing together EZH2 and JARID2, to exert its epigenetic function in embryonic stem cells ([@ref32]), breast cancer ([@ref56]), and aging endothelium ([@ref4]). However, in hypoxic cardiomyocytes, *Meg3* works as a decoy for FUS proteins, a factor required for DNA damage repair ([@ref13]). As result, cardiomyocytes enter apoptosis. This is a clear example of how a lncRNA can have different functions and partners depending on the cell type and the biological context.

One of the contributors to AMI impaired healing is the massive infiltration of immune cells, and it has been described that at least a part of the myeloid cells that migrate to the infarction come from the spleen ([@ref76]). Interestingly, a lncRNA termed *Lethe* has been shown to be downregulated in the spleen of aged individuals, and its function is the binding of NFκB subunit RelA, interfering with its pro-inflammatory function ([@ref68]). This could contribute to the impaired healing and therefore worsen AMI recovery in the elderly.

Recently, several lncRNAs, including some that are well described to act through other mechanisms, have been claimed to work as miRNA sponges that prevent their function in RNA interference. For instance, the hypertrophy-related gene *Myd88* is a target of *miR-489*, which is downregulated upon AngII stimulation due to the upregulation of the lncRNA CH-related factor (*Chrf*), which binds to the miRNA counteracting its inhibitory effect on *Myd88* expression ([@ref87]). It is worth to mention that there is still a controversy about this mechanism for lncRNA function ([@ref78]). It is unclear how the stoichiometry of these miRNA--lncRNA binding fits, as miRNAs are usually present in much higher copy numbers than lncRNAs in the cell, and most studies only show a single complementary site per lncRNA. In [Table 1](#TB1){ref-type="table"}, we summarize the lncRNAs that have been described as miRNAs sponges in the context of CVD.

###### 

LncRNAs acting as miRNA sponges in the context of CVD.

  **Disease**   **lncRNA**   **Reference**   **Sponged miRNA**   **miRNA target**   **Cell type**
  ------------- ------------ --------------- ------------------- ------------------ ---------------
  CH            *Ror*        [@ref31]        *miR-133*           Not studied        CM
  CH            *Hotair*     [@ref38]        *miR-19*            *Pten*             CM
  CH            *Plscr4*     [@ref47]        *miR-214*           *Mfn2*             CM
  CH            *Chrf*       [@ref87]        *miR-489*           *Myd88*            CM
  AMI           *Ftx*        [@ref45]        *miR-29b-1-5p*      *Bcl2l2*           CM
  AMI           *Apf*        [@ref85]        *miR-188-3p*        *Atg7*             CM
  AMI           *Carl*       [@ref88]        *miR-539*           *Phb2*             CM
  AMI           *Nrf*        [@ref86]        *miR-873*           *Ripk1/ripk3*      CM
  AMI           *Zfas1*      [@ref94]        *miR-150*           *Crp*              CM
  AMI           *Malat1*     [@ref29]        *miR-145*           *Tgfβ1*            FB
  Arrhythmia    *Kcnq1ot1*   [@ref74]        *miR-384b*          *Cacna1c*          CM
  Diabetic HF   *Kcnq1ot1*   [@ref96]        *miR-214-3p*        *Caspase 1*        CM

CM, cardiomyocytes; FB, fibroblasts.

Guide lncRNAs {#sec8}
-------------

A fibroblast-enriched lncRNA, Wisp2 super-enhancer-associated RNA (*Wisper*), is upregulated after AMI in mice and in patients with aortic stenosis, both diseases that trigger cardiac fibrosis and left ventricular (LV) dysfunction. Indeed, *Wisper* expression correlates with the extent of cardiac fibrosis. Silencing of *Wisper* decreases the expression of profibrotic genes, as *Col1a3* and *Tgfb2*, in cardiac but not lung fibroblasts, while CRISPR-on-mediated *Wisper* induction boosts the expression of these genes. Mice treated with GapmeRs targeting *Wisper* develop much less cardiac fibrosis after AMI induction, and consequently, conserve better LV function. Mechanistically, *Wisper* binds TIAR and retains it in the nucleus, guiding it to bind to and promote processing of lysil hydroxylase 2 mRNA, a mediator of collagen crosslinking ([@ref53]).

Another novel mechanism has been described for *Meg3* in cardiac fibroblasts in the development of HFpEF ([@ref66]). In a murine model of pressure-overload HF, *Meg3* was downregulated in cardiac fibroblasts in the late stages of cardiac remodeling. Downregulation of *Meg3* repressed expression of genes of the MMP family, specifically *Mmp2*. *Mmp2* is a target of the TGFβ1 pathway and contains a canonical p53-binding site in its promoter. Knockdown of *Meg3 in vivo* prevents *Mmp2* expression, ameliorating fibrosis, and diastolic dysfunction in pressure-overload hearts. The authors propose that, under stress conditions that trigger TGFβ1 pathway activation, *Meg3* binds p53 and directs it to the *Mmp2* promoter, inducing its expression and thereby promoting cardiac fibrosis.

In the previous cases, the lncRNA acted in trans, but lncRNAs can also act in cis. For instance, [@ref55] describe a lncRNA located antisense to *BDNF*, named *BDNF-AS*, that recruits EZH2 to the promoter of *BDNF* to epigenetically repress its expression. In a cardiac context, *Bdnf-as* has been shown to be necessary for *Bdnf* downregulation in an *in vitro* model of ischemia/reperfusion that mediates the response to cellular damage through the VEGF/AKT pathway ([@ref99]).

A recently described lncRNA involved in telomere protection and cellular senescence is telomeric repeat-containing RNA (*TERRA*). Although telomeres are heterochromatic regions, it has been demonstrated that these noncoding transcripts are transcribed from the subtelomere toward the telomere of several chromosomes. Particularly, the TERRA molecule arising from the q-arm of human chromosome 20 (*20q-TERRA)* has an important role in telomeric heterochromatin assembly, telomere length maintenance, and protection. *TERRA* transcripts recruit the PRC2 complex to the telomere, where it regulates the heterochromatic status of the telomere ([@ref57]). A role for *TERRA* in the cardiovascular system is, however, not yet described.

Scaffold and enhancer-associated lncRNAs {#sec9}
----------------------------------------

Although the binding of transcription factors to the promoter is the main determinant to activate the expression of a certain gene, it is important to stress the importance of enhancers in this process. An enhancer is a regulatory sequence in the DNA that lies relatively far away from the transcription start site but dictates the level of expression of its target gene and usually includes chromosomal looping to bring together the different regulatory proteins involved ([@ref60]). There is increasing evidence that lncRNAs can act as a scaffold to bind the regulators, transcription factors, DNA enhancer, and promoter sequences in the loop to activate the expression of a gene.

One of the typical features in the onset of HF is the re-expression of the cardiac fetal gene program. The study of the expression of mouse fetal enhancer *mm67*, *mm85*, *mm130*, and *mm132* revealed that they are associated with lncRNAs that are critical for their role in cardiac development and are also expressed in the adult heart. Moreover, RNA expression analysis at 7 days post-AMI showed that lncRNAs *mm67* and *mm85* and their target myocardin were downregulated, while *mm130* and *mm132* were upregulated at 14 days after AMI, which correlated with the expression of their target genes *Tbx20* and *endothelin-1* and reactivation of the cardiac fetal and stress signature markers βMHC, ANF, and BNP. These results were also replicated in a pressure-overload surgical model, proving the importance of enhancer regions in the response to cardiac stress ([@ref63]).

In a related publication of the same laboratory, mouse cardiac tissue was isolated 2 weeks after AMI and deep-sequenced to look for novel lncRNAs involved in the signaling cascades that lead to post-infarct HF. The authors found a set of lncRNAs that were differentially regulated compared to sham hearts, cardiac-specific and located in vicinity of genes with roles in cardiac development and transcriptional control, although their expression did not correlate with these. However, it was found that the expression of those lncRNAs was correlated with the appearance of echocardiography-defined physiological traits as ejection fraction or left ventricular diameter. Also, they were associated with active enhancer chromatin states, pointing to an enhancer-associated nature during cardiac precursor cell (CPC) transition to mature cardiomyocytes. For instance, *Novlnc6* is expressed from *mm74*, a cardiac enhancer active in the embryonic left ventricle and correlates with *Bmp10* and *Nkx2.5* expression during cardiac development and in dilated cardiomyopathy patients ([@ref62]).

A special type of enhancers are the so-called super enhancers, which are larger (up to 10 kb long) and are specialized in cell-identity regulation ([@ref27]). In the heart, the specification of cell identity is particularly important during cardiac regeneration, when CPCs need to differentiate into mature cardiomyocytes. In a recent publication, profiling of RNA expression in CPCs revealed a novel lncRNA, cardiac mesoderm enhancer-associated ncRNA (*CARMEN*) that is located in an active super enhancer region, is highly expressed during CPC differentiation, and mediates cardiac fate specification. In the adult heart, the three isoforms of *CARMEN* are differentially regulated in patients with dilated cardiomyopathy and CH. This lncRNA exert its function by binding to PRC2 components EZH2 and SUZ12 and recruiting them both in cis and in trans to repress target gene expression ([@ref61]).

Other lncRNAs regulated in cardiac diseases {#sec10}
-------------------------------------------

Profiling of lncRNAs expressed in cardiac tissue in a pressure-overload mouse model revealed a lncRNA that is upregulated in cardiomyocytes under prohypertrophic stimuli, named CH-associated transcript (*Chast*). *Chast* expression is activated by the CN/NFAT pathway, one of the canonical signaling pathways implicated in hypertrophy ([@ref25]). *Chast* gene is located near *Plekhm1* and acts in cis downregulating *Plekhm1* expression, which is necessary to trigger a hypertrophy gene expression profile. Indeed, viral-mediated overexpression of *Chast* in mice induces a spontaneous CH phenotype, while knockdown prevents and decreases CH after pressure-overload. It is unknown what the specific mechanism is that allows *Chast* to interfere with *Plekhm1* expression ([@ref83]).

Another lncRNA profiling study during aging in cardiac and skeletal muscles showed that the aging process induces differential expression of lncRNAs even in apparently similar tissues. In the heart, four lncRNAs are upregulated specifically in the aging cardiomyocyte. Cluster analysis revealed that this specific expression pattern correlates with negative regulation of myotube differentiation and muscle contraction ([@ref9]). In the same line, [@ref1] performed expression profiling of old versus earlier passage fibroblasts and found out numerous lncRNAs, including the known *MALAT1* and myocardial infarction-associated transcript *(MIAT*) and a novel lncRNA, termed senescence-associated lncRNA 1, that were downregulated during aging. Silencing of any of them triggers a senescent phenotype in cultured fibroblasts and may be of interest in cardiac aging.

A microarray-based RNA expression profiling in hearts of mice subjected to AMI for 24 h shows the upregulation of two novel lncRNAs, myocardial infarction-associated transcript 1 and 2 (*Mirt1* and *Mirt2*). *Mirt1* is expressed in the remote zone of the myocardium by cardiac fibroblasts and correlates with the expression of genes implicated in cardiac remodeling ([@ref98]). Knockdown of *Mirt1* partially prevented cardiac dysfunction, apoptosis and monocyte infiltration after AMI through inhibition of the NFκB pathway, although the mechanism is not fully studied ([@ref42]).

A study of the lncRNA expression profile of peripheral blood mononuclear cells (PBMNCs) in HF patients allowed for the identification of a novel HF-associated lncRNA, heart disease-associated transcript 2 (*HEAT2*), which is expressed in eosinophils and basophiles but not in other types of immune cells. *HEAT2* was found to promote PBMNC adhesion to the endothelium and transmigration, two important processes in the immune response initiation. *HEAT2* binds to H3K27me3 repressive marks, and it is thought to act by *trans*-regulation of gene expression ([@ref3]).

LncRNAs as biomarkers {#sec11}
=====================

The first time that the lncRNA *MIAT* was identified was in a large-scale association study in the Japanese population with the aim to identify single nucleotide polymorphisms (SNPs) in heart tissue that helped predicting a genetic risk for AMI. The authors found a locus containing a SNP with a strong association with AMI. This locus corresponds to a lncRNA that the authors named *MIAT*. Although the function of *MIAT* was not studied, it was suggested that it possibly binds to a transcription factor and increases transcriptional activity in the cell ([@ref30]). Another attempt of finding SNPs that predict coronary artery disease revealed an association between the risk of atherosclerosis and presence in plasma of different variants of antisense noncoding RNA in the INK4 locus (*ANRIL*) ([@ref44]; [@ref28]; [@ref97]). *ANRIL* is described to bind two proteins in the PRC1 and PRC2 complexes to induce histone methylation and silencing of the *CDKN2A/B* locus, which is a key for cell survival ([@ref11]).

In 2014, two different studies in plasma from CVD patients revealed new potential biomarker lncRNAs. [@ref37] found that the presence of long intergenic noncoding RNA predicting cardiac remodeling (*LIPCAR*) in plasma of recovering AMI patients was a predictor of adverse cardiac remodeling and HF. On the other side, [@ref82] studied the expression profile of five lncRNAs (*aHIF*, *ANRIL*, *KCNQ1OT1*, *MIAT*, and *MALAT1*) in PBMNCs of patients with AMI and found that the last four were significantly downregulated in patients with ST-segment-elevation AMI, and predicted the individuals that would suffer ventricular remodeling, particularly in the case of *ANRIL* and *KCNQ1OT1*. A recent study in the Chinese population has shown two lncRNAs as biomarkers of HF: noncoding repressor of NFAT (*NRON*) and *MHRT*. *NRON* and *MHRT* are upregulated in the plasma of HF patients and correlate with presence of other cardiac biomarkers in blood ([@ref95]).

Conclusion {#sec12}
==========

The advances in healthcare have increased the lifespan in the Western societies, but life quality in the elderly is still lagging due to the high prevalence of cardiac diseases. There is increasing evidence for the role of lncRNAs in CVDs and aging, including their potential as biomarkers of worsening prognosis after cardiac events. However, the field is still too novel to bring a therapeutic option for patients, and more profound studies are required, as well as a critical view of the discipline to completely and verifiably understand the molecular mechanisms that define lncRNA function in the different cell subsets and under different pathological contexts.
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